Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Procter & Gamble Health Ltd (PGHL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500126 NSE: PGHL Pharmaceuticals & Drugs | Small Cap | Procter&Gamble Healt Share Price
₹5,933.70 11.30 (0.19%)
As on 14-Aug'26 16:59
Procter & Gamble Health Ltd (PGHL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500126 NSE: PGHL Pharmaceuticals & Drugs | Small Cap | Procter&Gamble Healt Share Price
₹5,933.70 11.30 (0.19%)
As on 14-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹9,850 Cr.
Current Price
₹5,933.7
52-Week Low / High
₹4,700 / 6,955
TTM EPS
₹215
TTM Sales
₹1,433 Cr.
Book Value per Share
₹370.9
P/E Ratio
27.60
Lower than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
16.00
Higher than its 5-year historical median
Price to Sales (P/S)
6.87
In line with its 5-year historical median
EV/EBITDA
20.00
Lower than its 5-year historical median
Dividend Yield
3.45%
Profitability Efficiency
Return on Equity (ROE)
62.18%
Outperforms industry median
Return on Capital Employed (ROCE)
84.86%
Outperforms industry median
Return on Assets (ROA)
41.65%
Operating Profit Margin
32.3%
Net Profit Margin
23.22%
Gross Profit Margin
30.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
13.04%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
42.27%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
39.46%
Asset Quality
Promoter Holding
51.82%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹599 Cr.
Equity
₹16.6 Cr.
Face Value
₹10
All Time Low / High
₹114.00 / 7499.95
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Procter & Gamble Health Ltd a good quality company?
Procter & Gamble Health Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Procter & Gamble Health Ltd performance compare with that of its Peers?
Revenue growth of Procter & Gamble Health Ltd vs industry peers?
Procter & Gamble Health Ltd revenue CAGR is 4.79%, compared to the industry median CAGR of 5.75%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Procter & Gamble Health Ltd?
Promoters hold 51.82% of the Procter & Gamble Health Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Procter & Gamble Health Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 23.7% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Procter & Gamble Health Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Mar'24 | Jun'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 14.2% | 13.9% | 29% | 29.1% | 38.5% | 46.1% | 0% | 42.5% | 58.1% | 84.9% | - |
| Value Creation Index ⓘ | 0.0 | 0.0 | 1.2 | 1.2 | 1.9 | 2.4 | NA | 2.2 | 3.3 | 5.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 698 | 849 | 904 | 1,009 | 1,114 | 1,230 | 1,151 | 1,151 | 1,246 | 1,408 | 1,433 |
| Sales YoY Gr. | - | 21.6% | 6.5% | 11.6% | 10.5% | 10.3% | -6.4% | 0% | 8.2% | 13% | - |
| Adj EPS ⓘ | 28.8 | 58.1 | 102.2 | 107.1 | 116.5 | 137.8 | 129.7 | 129.7 | 188.5 | 197.1 | 215 |
| YoY Gr. | - | 102.1% | 75.9% | 4.8% | 8.8% | 18.3% | -5.9% | 0% | 45.3% | 4.6% | - |
| BVPS (₹) ⓘ | 441.7 | 927.8 | 363.2 | 421.6 | 367 | 447.6 | 319.1 | 319.1 | 427.4 | 312.9 | 370.9 |
| Adj Net Profit ⓘ | 47.8 | 96.5 | 170 | 178 | 193 | 229 | 215 | 215 | 313 | 327 | 357 |
| Cash Flow from Ops. ⓘ | 53.7 | -130 | 157 | 247 | 170 | 236 | 228 | 228 | 225 | 338 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 8.1% | 4.8% | 6.9% | 13% | ||||
| Adj EPS ⓘ | 23.9% | 11.1% | 15% | 4.6% | ||||
| BVPSⓘ | -3.8% | -3.1% | -0.7% | -26.8% | ||||
| Share Price | 23.7% | 1.6% | 3.9% | -5.6% | ||||
Key Financial Parameters ⓘ
| Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Mar'24 | Jun'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 6.8 | 8.5 | 20.8 | 22.1 | 29.3 | 33.5 | 33.4 | 33.4 | 43.6 | 61.7 | 62.9 |
| Op. Profit Mgn % ⓘ | 10.1 | 17 | 23.4 | 24.5 | 24.1 | 26.4 | 26.6 | 26.6 | 34.1 | 32.3 | 32.5 |
| Net Profit Mgn % ⓘ | 6.8 | 11.4 | 18.8 | 17.6 | 17.4 | 18.6 | 18.7 | 18.7 | 25.1 | 23.2 | 24.9 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 500 | 486 | 346 | 491 | 438 | 423 | 290 | 290 | 146 | 111 | 78 |
| Cash Conv. Cycle ⓘ | 88 | 49 | 12 | -3 | -22 | -31 | -33 | -33 | -36 | -12 | 47 |
Valuation of Procter&Gamble Healt - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 993 | 698 | 849 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 |
| Operating Expenses ⓘ + | 877 | 628 | 705 | 1,042 | 763 | 847 | 905 | 845 | 616 | 955 |
| Operating Profit ⓘ | 116 | 71 | 144 | 314 | 246 | 268 | 325 | 306 | 318 | 453 |
| Operating Profit Margin (%) | 11.6% | 10.1% | 17.0% | 23.2% | 24.4% | 24.0% | 26.4% | 26.6% | 34.1% | 32.2% |
| Other Income ⓘ + | 24 | 30 | 28 | 70 | 18 | 13 | 18 | 16 | 10 | 21 |
| Interest ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Depreciation ⓘ | 25 | 19 | 21 | 29 | 30 | 27 | 28 | 27 | 17 | 24 |
| Profit Before Tax ⓘ | 115 | 99 | 158 | 355 | 233 | 253 | 314 | 273 | 312 | 450 |
| Tax ⓘ | 36 | 38 | 56 | 101 | 56 | 61 | 85 | 72 | 77 | 123 |
| Profit After Tax | 79 | 61 | 102 | 254 | 177 | 193 | 229 | 201 | 234 | 327 |
| PAT Margin (%) | 8.0% | 8.7% | 12.0% | 18.7% | 17.5% | 17.3% | 18.7% | 17.5% | 25.1% | 23.2% |
| Adjusted EPS (₹) | 47.7 | 36.8 | 61.3 | 153.1 | 106.5 | 116.0 | 138.2 | 121.1 | 141.2 | 196.9 |
| Dividend Payout Ratio (%) | 23.10% | 40.80% | 717.90% | 150.30% | 122.10% | 45.30% | 68.70% | 214.80% | 88.50% | 104.10% |
| PARTICULARS | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 664 | 733 | 1,540 | 904 | 700 | 609 | 743 | 530 | 532 | 519 | |
| Debt + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 75 | 83 | 91 | 124 | 179 | 172 | 237 | 167 | 172 | 192 | |
| Others Liabilities ⓘ | 624 | 699 | 951 | 1,084 | 1,099 | 1,157 | 1,253 | 64 | 55 | 99 | |
| Total Liabilities ⓘ | 1,363 | 1,516 | 2,583 | 2,112 | 1,978 | 1,938 | 2,233 | 761 | 759 | 811 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 119 | 140 | 124 | 98 | 101 | 110 | 142 | 127 | 112 | 100 | |
| CWIP ⓘ | 30 | 9 | 17 | 21 | 39 | 41 | 32 | 6 | 11 | 14 | |
| Investments ⓘ | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 164 | 158 | 113 | 134 | 118 | 115 | 135 | 109 | 109 | 137 | |
| Trade Receivables | 107 | 123 | 66 | 95 | 60 | 83 | 116 | 85 | 145 | 164 | |
| Cash Equivalents | 279 | 278 | 1,243 | 639 | 469 | 325 | 440 | 244 | 189 | 185 | |
| Others Assets ⓘ | 636 | 738 | 1,018 | 1,124 | 1,191 | 1,264 | 1,368 | 189 | 193 | 211 | |
| Total Assets ⓘ | 1,363 | 1,516 | 2,583 | 2,112 | 1,978 | 1,938 | 2,233 | 761 | 759 | 811 | |
| PARTICULARS | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 107 | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | 338 |
| Cash Flow From Investing Activity ⓘ + | -75 | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | 1 |
| Cash Flow From Financing Activity ⓘ + | -15 | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | -344 |
| Net Cash Flow ⓘ | 17 | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 | -5 |
| PARTICULARS | Dec'16 | Dec'17 | Dec'18 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.61 | 8.74 | 8.95 | 20.79 | 22.04 | 29.41 | 33.94 | 31.58 | 44.15 | 62.18 |
| ROCE (%) | 18.35 | 14.16 | 13.9 | 29.01 | 29.08 | 38.45 | 46.07 | 42.52 | 58.05 | 84.86 |
| Asset Turnover Ratio | 0.71 | 0.49 | 0.41 | 0.58 | 0.49 | 0.6 | 0.64 | 0.84 | 1.35 | 2 |
| PAT to CFO Conversion(x) | 1.35 | 0.89 | -1.27 | 0.93 | 1.4 | 0.88 | 1.03 | 1.13 | 0.72 | 1.03 |
| Working Capital Days | ||||||||||
| Receivable Days | 41.40 | 58.90 | 40.60 | 21.70 | 28.10 | 22.20 | 27.40 | 29.10 | 40.90 | 36.10 |
| Inventory Days | 58.60 | 82.50 | 58.30 | 33.30 | 45.70 | 36.20 | 34.40 | 35.40 | 38.80 | 28.70 |
| Payable Days | 61.20 | 118.30 | 116.20 | 91 | 177.10 | 188.50 | 206.40 | 223.10 | 235.40 | 181.90 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Procter & Gamble Health Ltd FAQs
The current trading price of Procter&Gamble Healt on 14-Aug-2026 16:59 is ₹5,933.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Procter&Gamble Healt stood at ₹9,849.6 Cr
The latest P/E ratio of Procter&Gamble Healt as of 13-Aug-2026 is 27.60.
The latest P/B ratio of Procter&Gamble Healt as of 13-Aug-2026 is 16.00.
The 52-week high of Procter&Gamble Healt is ₹6,955 and the 52-week low is ₹4,699.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Procter&Gamble Healt is ₹1,433 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Procter & Gamble Health Ltd is a good quality company.
The key valuation ratios of Procter & Gamble Health Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Procter & Gamble Health Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Procter & Gamble Health Ltd
Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.
On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.
Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.
Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.
Business area of the company
Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.
Brands of the company
- Neurobion
- Evion
- Seven Seas
- Nasivion
- Polybion
- Livogen
Awards and achievements
- 2015-16: Merck Goa plant was awarded 1st prize in safety called “Gomant Sarvochcha Suraksha Puraskar”. This is consecutive 2nd time Merck Goa plant bagged 1st prize in safety. Prior to that Merck Goa plant bagged 2nd prize in safety “Gomant Uchcha Suraksha Puraskar” for two consecutive years.
- 2016-17: Consumer activation done for Neurobion under ‘True Heroes’ campaign won laurels at the Global level to receive President’s Award in 2017.
- 2017-18: Nasivion continued to be the Doctors’ trusted No. 1 Nasal Decongestant.
- 2019-20: Neurobion bagged three awards viz. Nicholas Hall Marketing Excellence Award; CIMS Trusted Brand of the Year; and ABP News Brand Excellence Award.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
